Medicare improperly paid for seniors' Viagra; Bayer gets FDA OK for Gadavist;

@FiercePharma: Lilly animal health unit offers to buy Janssen outfit. Report | Follow @FiercePharma  

> The U.S. Medicare program improperly spent more than $3 million in 2007 and 2008 to buy Pfizer's Viagra and other erectile dysfunction drugs for senior citizens, government investigators said. Story

> Bayer HealthCare Pharmaceuticals has received FDA approval for its Gadavist (gadobutrol) imaging agent. Item

> Pozen said India's No.2 drugmaker Dr Reddy's Laboratories Ltd has filed with U.S. health regulators for a copycat version of its pain drug Vimovo. News

> Canada amends regulations on adverse drug reaction reporting. Report

Biotech News

@FierceBiotech: Will Pfizer divest a big chunk of its operations? News | Follow @FierceBiotech

@JohnCFierce: Seattle-based Koronis says forget Nasdaq, he'll list in London. To raise $15 million? Story | Follow @JohnCFierce

> Pfizer in talks with CROs to fill its Sandwich R&D hub. Item 

> Qiagen plots another diagnostics buyout deal. Story

> Impax Labs' Parkinson's drug aces late-stage clinical trial. News

> Novartis, Incyte ready worldwide apps as cancer drug clears Ph3. Report 

Biotech Research News

> Florida lawmakers tell Scripps to show them the jobs. Report

> Nanomaterials incarcerate prostate cancer cells. News 

> Genes are still looking hot, survey says. Item

> Research sheds light on anxiety disorders. Article 

> Pentagon may have hard time cutting cancer research budget. Story 

> Media report high hopes for adult stem cells. News 

Manufacturing News

> Cheers become jeers on KV's Makena pricing. News

> Pharma makes top-counterfeits list. Item

> Earthquake in Japan compromises supply chain. Report

> McNeil's consent decree terms could have been worse. Item 

> Decree a no-confidence vote in McNeil. Story

> USP edits drug labels for better patient compliance. Article

And Finally... To every drug there is a season? Swedish researchers find that efficacy varies according to how much sunlight the patient is exposed to. Article

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.